Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31, 2025

Titan Securities' board approved standalone and consolidated unaudited results for Q3 FY26 (ended Dec 31, 2025) on Feb 12, 2026. On a standalone basis, total income fell sharply to Rs. 101.25 lakhs from Rs. 334.90 lakhs in the same quarter last year, a drop of nearly 70%. Standalone profit after tax also declined to Rs. 37.88 lakhs (vs Rs. 71.37 lakhs in Q3 FY25), with EPS falling to Rs. 0.15 from Rs. 0.29. However, on a consolidated basis, PAT jumped to Rs. 367.18 lakhs in Q3 FY26 from Rs. 254.34 lakhs a year ago (about 44% growth), driven mainly by Rs. 329.30 lakhs share of profit from associates Titan Biotech and Peptech Biosciences. Consolidated EPS rose to Rs. 1.47 from Rs. 1.02. The new statutory auditor, Goyal Nagpal & Co, issued unmodified review reports, and noted that prior period results were reviewed by the predecessor audit firm, indicating a recent auditor change.